On April 1, 2025, Eli Lilly & Co. sent a letter to the Georgia Board of Nursing urging them to take certain actions to address nurse practitioners (NPs) who continue to prescribe compounded versions of tirzepatide—the active ingredient in Mounjaro® and Zepbound®—following its removal from the FDA’s drug shortage list. What Does the Letter Say?…